Pluri (US:PLUR) Globenewswire·2026-02-18 13:00Core Viewpoint - Pluri Inc. has received a patent from the China National Intellectual Property Administration for its proprietary 3D immune cell expansion and activation technology, enhancing its global intellectual property portfolio and positioning the company for growth in the rapidly expanding cell therapy market in China [1][2][4]. Intellectual Property Expansion - The newly granted patent (Patent No. Cn 119301238 b) adds to Pluri's existing patents in the U.S., Japan, Korea, Australia, and Israel, supporting the company's strategy for global collaboration and licensing agreements in immune cell therapy products [2][6]. - The patent family encompasses large-scale production of various immune cell types, including both unmodified and genetically modified cells, across multiple therapeutic areas [3]. Market Positioning - Securing the patent in China is crucial as the country is a dynamic market for CAR-T and advanced cell therapies, driven by clinical adoption, manufacturing infrastructure, and investment [4]. - Pluri's patented 3D platform addresses industry bottlenecks and enables mass production of immune cells, enhancing cost-efficiency and ensuring quality control through an automated, closed-loop process [5]. Strategic Partnerships - With patent protection across major pharmaceutical markets, Pluri serves as an "IP Bridge" for partners developing therapies on its platform, facilitating international licensing and development [6]. - The broad coverage of intellectual property supports global pharmaceutical companies in operating in China and allows Chinese biotech firms to pursue international expansion [6]. Technology Validation - The CEO of Pluri emphasized that securing patent protection in China validates the novelty and scalability of the company's technology, aiming to provide partners with a globally protected manufacturing platform for large-scale immune cell production [7].